Biomarin Pharmaceutical (BMRN) Assets: 2009-2025
Historic Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $7.6 billion.
- Biomarin Pharmaceutical's Assets rose 11.15% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 billion, marking a year-over-year increase of 11.15%. This contributed to the annual value of $7.0 billion for FY2024, which is 2.15% up from last year.
- Biomarin Pharmaceutical's Assets amounted to $7.6 billion in Q3 2025, which was up 2.13% from $7.5 billion recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Assets ranged from a high of $7.6 billion in Q3 2025 and a low of $5.8 billion during Q1 2021.
- Its 3-year average for Assets is $7.0 billion, with a median of $6.9 billion in 2024.
- The largest annual percentage gain for Biomarin Pharmaceutical's Assets in the last 5 years was 22.91% (2021), contrasted with its biggest fall of 2.93% (2021).
- Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Assets stood at $6.0 billion in 2021, then rose by 6.17% to $6.4 billion in 2022, then grew by 7.32% to $6.8 billion in 2023, then climbed by 2.15% to $7.0 billion in 2024, then increased by 11.15% to $7.6 billion in 2025.
- Its Assets was $7.6 billion in Q3 2025, compared to $7.5 billion in Q2 2025 and $7.1 billion in Q1 2025.